<DOC>
	<DOCNO>NCT02332473</DOCNO>
	<brief_summary>This study multi-center , randomize , prospective open-label study assess efficacy safety combination peginterferon alfa-2b ( 40kD , Y-shape ) GM-CSF interferon-naïve chronic hepatitis B patient HBeAg positive . Patients randomize one 2 group receive different antiviral treatment .</brief_summary>
	<brief_title>A Prospective Study Combination Peginterferon Alfa-2b ( 40kD , Y-shape ) GM-CSF Chronic Hepatitis B</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Peginterferon alfa-2b</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>18yrs≤age≤65yrs . 17≤BMI ( body mass index ) ≤28 . HBsAg positive≥6 month . Serum HBV DNA≥20,000IU/ml , HBsAg positive HBeAg positive screening . 2ULN≤ALT≤10ULN ( ULN=upper limit normal ) screening . Pregnancy test must negative female patient childbearing potential . All patient take effective birth control measure treatment 6 month treatment . Agree participate study sign inform consent . Pregnant lactating female Interferon treatment history , use nucleos ( ) ide analogues chronic hepatitis B treatment within previous 6 month , evidence nucleosi ( ) ide analogue resistance . Receiving strong immunomodulatory agent ( e.g. , steroid , thymosin ) two week 6 month prior screen . Receiving hepatotoxicity agent ( e.g. , aczone , erythromycin , fluconazole , ketoconazole , rifampicin ) two week 6 month prior screen . Coinfected active hepatitis A , hepatitis C , hepatitis D , and/or human immunodeficiency virus ( HIV ) . History evidence medical condition associate chronic liver disease viral hepatitis ( e.g. , autoimmune hepatitis , alcoholic liver disease , toxin exposure . Suffering acute chronic infectious disease . Mental disorder physical disability , family history neurological psychiatric disorder . Neutrophil count &lt; 1500 cells/mm3 , platelet count &lt; 90000 cells/mm3 screening . ChildPugh≥B , evidence liver decompensation ( e.g . serum albumin &lt; 35g/L , prothrombin time &gt; 3 second prolonged , serum bilirubin &gt; 2ULN , prothrombin activity &lt; 60 % , history liver decompensation ) . Serum creatinine level &gt; ULN screen period . Serum creatine kinase level &gt; 2ULN except physiological factor ( e.g. , exercise ) . AFP &gt; 100ng/L . If 50ng/L &lt; AFP &lt; 100ng/L screening , retest 2 week later , AFP &lt; 50ng/L enrolled , v , exclude . Hepatocarcinoma suffer malignant tumor . Autoimmune disease ( e.g. , psoriasis , systemic lupus erythematosus ) . Moderate severe hypertension , mild hypertension without well control . With well control endocrine disease ( e.g. , thyroid dysfunction , diabetes mellitus ) . Drug abusing , alcoholism . HBeAb positive HBsAb positive screening . Allergic interferon , GMCSF , fragment study drug . Other condition opinion investigator preclude enrollment study ( e.g. , low compliance ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>